Filter by
Selections
March 8, 2024
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Read MoreJanuary 5, 2024
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
Read MoreJanuary 3, 2024
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
Read MoreDecember 29, 2023
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreDecember 21, 2023